ABUS vs KEYS
Arbutus Biopharma Corp (ABUS) versus Keysight Technologies Inc (KEYS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
Not investment advice. Open the ABUS and KEYS stock pages for the full models.
Not investment advice.